

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review

URL: <https://marketpublishers.com/r/A16EE7FD068EN.html>

Date: July 25, 2018

Pages: 56

Price: US\$ 125.00

ID: A16EE7FD068EN

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Jun 20,2018: Alnylam Pharmaceuticals Announces Senior Management Changes

May 15,2018: Alnylam Appoints Colleen Reitan to the Board of Directors

May 08,2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics

May 03,2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and **Highlights** Recent Period Activity

Apr 20,2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Alnylam Pharmaceuticals Inc - Key Facts
Alnylam Pharmaceuticals Inc - Key Employees
Alnylam Pharmaceuticals Inc - Key Employee Biographies
Alnylam Pharmaceuticals Inc - Major Products and Services
Alnylam Pharmaceuticals Inc - History
Alnylam Pharmaceuticals Inc - Company Statement
Alnylam Pharmaceuticals Inc - Locations And Subsidiaries
Head Office

Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Alnylam Pharmaceuticals Inc - Business Description
Alnylam Pharmaceuticals Inc - Corporate Strategy
Alnylam Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Alnylam Pharmaceuticals Inc - Strengths
Alnylam Pharmaceuticals Inc - Weaknesses
Alnylam Pharmaceuticals Inc - Opportunities
Alnylam Pharmaceuticals Inc - Threats
Alnylam Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Alnylam Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors
May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights
Recent Period Activity
Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation
Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam
Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease
Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing
Jan 10, 2018: Regeneron forms consortium to advance human gene sequencing
Jan 07, 2018: Alnylam Announces 2018 Corporate Goals

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us

Disclaimer

LIST OF TABLES

Alnylam Pharmaceuticals Inc, Key Facts
Alnylam Pharmaceuticals Inc, Key Employees
Alnylam Pharmaceuticals Inc, Key Employee Biographies
Alnylam Pharmaceuticals Inc, Major Products and Services
Alnylam Pharmaceuticals Inc, History
Alnylam Pharmaceuticals Inc, Subsidiaries
Alnylam Pharmaceuticals Inc, Joint Venture
Alnylam Pharmaceuticals Inc, Key Competitors
Alnylam Pharmaceuticals Inc, Ratios based on current share price
Alnylam Pharmaceuticals Inc, Annual Ratios
Alnylam Pharmaceuticals Inc, Annual Ratios (Cont.1)
Alnylam Pharmaceuticals Inc, Interim Ratios
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Alnylam Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Alnylam Pharmaceuticals Inc, Performance Chart (2013 - 2017)
Alnylam Pharmaceuticals Inc, Ratio Charts
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Sylentis SAU
SOM Biotech SL
Quark Pharmaceuticals Inc
Prothena Corp Plc
Pfizer Inc
Marina Biotech Inc
Ionis Pharmaceuticals Inc
GlaxoSmithKline Plc
Dicerna Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc

I would like to order:

Product name: Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/A16EE7FD068EN.html>
Product ID: A16EE7FD068EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/A16EE7FD068EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**